Background: Amyloidosis includes a group of diseases characterized by the extracellular deposition of various fibrillary proteins that can autoaggregate in a highly abnormal fibrillary conformation. The amyloid precursor protein of systemic light-chain (AL) amyloidosis is comprised of monoclonal light chains that are due to plasma cell dyscrasia. The clinical presentation of patients with AL amyloidosis varies from patient to patient. Current treatment strategies target the clone in order to decrease the production of the pathologic light chains. Recent advances in therapy have helped many patients with AL amyloidosis achieve hematologic and organ responses. Summary: AL amyloidosis is the most common type of systemic amyloidosis in China with increasing morbidity and a high mortality rate. The clinical presentation of AL amyloidosis is variable, and the median overall survival was found to be 36.3 months. The disease prognosis and risk stratification are linked to serialized measurement of cardiac biomarkers and free light chains. The treatment of AL amyloidosis is mainly based on chemotherapy and autologous hematopoietic stem cell transplantation (ASCT). The use of novel agents (thalidomide, lenalidomide, and bortezomib) alone and in combination with steroids and alkylating agents has shown efficacy and continues to be explored. Key Messages: AL amyloidosis is the most common type of systemic amyloidosis in China with increasing morbidity and a high mortality rate. The lack of prospective clinical trials using the current therapies is a challenge for evidence-based decision making concerning the treatment of AL amyloidosis. Facts from East and West: (1) AL amyloidosis is the most prevalent type of amyloidosis accounting for 65% of the amyloidosis-diagnosed patients in the UK and for 93% of the amyloidosis-diagnosed patients in China. The predisposition of men over women to develop AL amyloidosis might be higher in China than in Western countries (2:1 vs. 1.3:1). Both in the East and West, incidence increases with age. At the time of diagnosis, edema is twice as frequent and the proportion of renal involvement is higher in Chinese compared to Western patients. (2) Melphalan followed by ASCT is the current standard therapy but is restricted to eligible patients. The efficacy and safety of bortezomib combined with dexamethasone were proven in Western patients and recently confirmed in a Chinese cohort. Recent studies in China and the US indicate that bortezomib induction prior to ASCT increases the response rate. Thalidomide and lenalidomide have shown benefit, but toxicity and lack of clinical evidence exclude these agents from first-line therapy. The green tea extract epigallocatechin-3-gallate is under investigation as an inhibitor of AL amyloid formation and a compound that might dissolve amyloid.

Keywords:
Autologous stem cell transplantation, Chemotherapy, China, Clinical presentation, Systemic light-chain amyloidosis
1.
Feng Z, Liu C, Guan X, Mor V: China's rapidly aging population creates policy challenges in shaping a viable long-term care system. Health Aff (Millwood) 2012;31:2764-2773.
2.
Liu ZH: Nephrology in China. Nat Rev Nephrol 2013;9:523-528.
3.
Chen W, Zheng R, Zeng H, Zhang S, He J: Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2-12.
4.
Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
5.
Li LS, Liu ZH: Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004;66:920-923.
6.
Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M: Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010;6:417-429.
7.
Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA: Immunoglobulin light chain amyloidosis. Expert Rev Hematol 2014;7:143-156.
8.
Cohen AD, Comenzo RL: Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010;2010:287-294.
9.
Zhu P, Zhou FD, Zhao MH: The renal histopathology spectrum of elderly patients with kidney diseases: a study of 430 patients in a single Chinese center. Medicine (Baltimore) 2014;93:e226.
10.
Jin B, Zeng C, Ge Y, Le W, Xie H, Chen H, et al: The spectrum of biopsy-proven kidney diseases in elderly Chinese patients. Nephrol Dial Transplant 2014;29:2251-2259.
11.
Zhou FD, Shen HY, Chen M, Liu G, Zou WZ, Zhao MH, et al: The renal histopathological spectrum of patients with nephrotic syndrome: an analysis of 1,523 patients in a single Chinese centre. Nephrol Dial Transplant 2011;26:3993-3997.
12.
Huang X, Wang Q, Jiang S, Chen W, Zeng C, Liu Z: The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J 2015;8:120-126.
13.
Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA: Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid 2005;12:120-126.
14.
Yao Y, Wang SX, Zhang YK, Qu Z, Liu G, Zou WZ: A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transplant 2013;28:689-697.
15.
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757.
16.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995.
17.
Kastritis E, Dimopoulos MA: Recent advances in the management of AL amyloidosis. Br J Haematol 2016;172:170-186.
18.
Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, et al: Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (MSMART) consensus statement. Mayo Clin Proc 2015;90:1054-1081.
19.
Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al: Guidelines on the management of AL amyloidosis. Br J Haematol 2015;168:186-206.
20.
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.
21.
Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-3670.
22.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al: Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317-2325.
23.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al: New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-4549.
24.
Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-1037.
25.
Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-298.
26.
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al: A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126:612-615.
27.
Huang X, Wang Q, Chen W, Ren G, Liu Z: Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement. Amyloid 2016, Epub ahead of print.
28.
Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, et al: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-261.
29.
Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al: Lenalidomide, cyclophosphamide, and dexamethasone (CRD) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119:4860-4867.
30.
Sanchorawala V: High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am 2014;28:1131-1144.
31.
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
32.
Moreau P: Autologous stem cell transplantation for AL amyloidosis: a standard therapy? Leukemia 1999;13:1929-1931.
33.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A: Update on treatment of light chain amyloidosis. Haematologica 2014;99:209-221.
34.
Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, et al: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med 2014;12:2.
35.
Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, et al: Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant 2015;21:1445-1451.
36.
Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, et al: Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant 2015;50:914-917.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.